FDMT
Income statement / Annual
Last year (2023), 4D Molecular Therapeutics, Inc.'s total revenue was $20.72 M,
an increase of 562.29% from the previous year.
In 2023, 4D Molecular Therapeutics, Inc.'s net income was -$100.84 M.
See 4D Molecular Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$20.72 M
|
$3.13 M
|
$18.04 M
|
$13.61 M
|
$6.99 M
|
$14.13 M
|
$5.79 M
|
| Cost of Revenue |
$97.10 M |
$3.88 M |
$3.02 M |
$53.04 M |
$38.72 M |
$18.36 M |
$13.57 M |
| Gross Profit |
-$76.37 M |
-$751,000.00 |
$15.02 M |
-$39.43 M |
-$31.73 M |
-$4.23 M |
-$7.78 M |
| Gross Profit Ratio |
-3.69 |
-0.24 |
0.83 |
-2.9 |
-4.54 |
-0.3 |
-1.34 |
| Research and Development
Expenses |
$97.10 M
|
$80.25 M
|
$61.36 M
|
$53.04 M
|
$38.72 M
|
$18.36 M
|
$13.57 M
|
| General & Administrative
Expenses |
$36.49 M
|
$32.91 M
|
$28.01 M
|
$17.24 M
|
$13.90 M
|
$6.17 M
|
$3.49 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$36.49 M
|
$32.91 M
|
$28.01 M
|
$17.24 M
|
$13.90 M
|
$6.17 M
|
$3.49 M
|
| Other Expenses |
$0.00 |
$2.54 M |
$16,000.00 |
-$181,000.00 |
-$46,000.00 |
-$2,000.00 |
-$40,000.00 |
| Operating Expenses |
$133.59 M |
$113.16 M |
$89.37 M |
$70.28 M |
$52.61 M |
$24.53 M |
$17.06 M |
| Cost And Expenses |
$133.59 M |
$113.16 M |
$89.37 M |
$70.28 M |
$52.61 M |
$24.53 M |
$17.06 M |
| Interest Income |
$12.21 M |
$2.57 M |
$137,000.00 |
$152,000.00 |
$1.50 M |
$850,000.00 |
$89,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$5.75 M
|
$3.88 M
|
$3.02 M
|
$1.44 M
|
$1.00 M
|
$697,000.00
|
$626,000.00
|
| EBITDA |
-$107.12 M
|
-$106.15 M
|
-$68.31 M
|
-$55.22 M
|
-$44.62 M
|
-$9.70 M
|
-$10.65 M
|
| EBITDA Ratio |
-5.17 |
-35.17 |
-3.95 |
-4.06 |
-5.65 |
-0.69 |
-1.84 |
| Operating Income Ratio
|
-5.45
|
-35.17
|
-3.95
|
-4.16
|
-7.27
|
-0.74
|
-1.95
|
| Total Other
Income/Expenses Net |
$12.03 M
|
$2.54 M
|
$16,000.00
|
-$29,000.00
|
$1.46 M
|
$848,000.00
|
$49,000.00
|
| Income Before Tax |
-$100.84 M |
-$107.49 M |
-$71.32 M |
-$56.69 M |
-$49.31 M |
-$9.55 M |
-$11.22 M |
| Income Before Tax Ratio
|
-4.87
|
-34.35
|
-3.95
|
-4.16
|
-7.06
|
-0.68
|
-1.94
|
| Income Tax Expense |
$0.00 |
-$6.42 M |
-$3.02 M |
-$152,000.00 |
$3.63 M |
$848,000.00 |
-$89,000.00 |
| Net Income |
-$100.84 M |
-$101.08 M |
-$68.30 M |
-$56.54 M |
-$52.94 M |
-$9.55 M |
-$11.22 M |
| Net Income Ratio |
-4.87 |
-32.3 |
-3.79 |
-4.15 |
-7.58 |
-0.68 |
-1.94 |
| EPS |
-2.58 |
-3.12 |
-2.46 |
-2.12 |
-2 |
-0.76 |
-0.76 |
| EPS Diluted |
-2.58 |
-3.12 |
-2.46 |
-2.12 |
-2 |
-0.76 |
-0.76 |
| Weighted Average Shares
Out |
$39.13 M
|
$32.35 M
|
$27.73 M
|
$26.68 M
|
$26.49 M
|
$12.52 M
|
$14.84 M
|
| Weighted Average Shares
Out Diluted |
$39.13 M
|
$32.35 M
|
$27.73 M
|
$26.68 M
|
$26.49 M
|
$12.52 M
|
$14.84 M
|
| Link |
|
|
|
|
|
|
|
